Neuropsychiatric disorders correction in Alzheimer's disease
Behavioral and neuropsychiatric symptoms occur in 80% of patients with Alzheimer's disease (AD) and represent one of the most common reasons for early hospitalization and increased treatment costs. It is believed that the development of mental disorders (MD) is a marker of a number of additiona...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2022-06-01
|
| Series: | Неврология, нейропсихиатрия, психосоматика |
| Subjects: | |
| Online Access: | https://nnp.ima-press.net/nnp/article/view/1824 |
| _version_ | 1827062692445159424 |
|---|---|
| author | N. N. Koberskaya |
| author_facet | N. N. Koberskaya |
| author_sort | N. N. Koberskaya |
| collection | DOAJ |
| description | Behavioral and neuropsychiatric symptoms occur in 80% of patients with Alzheimer's disease (AD) and represent one of the most common reasons for early hospitalization and increased treatment costs. It is believed that the development of mental disorders (MD) is a marker of a number of additional adverse outcomes in patients with AD. The disease is accompanied by the development of other behavioral disorders, the most unpleasant of which are agitation (excitation) and aggression. The article discusses the causes and factors that can provoke the development of MD in AD. Traditionally used pharmacotherapeutic methods for the treatment of MD in AD in this age group have limited efficacy and are characterized by high toxicity. Antipsychotics are often associated with serious side effects and increased mortality in patients with dementia. A clinical case of AD with the development of neuropsychiatric disorders is presented. We discuss the issue of nonpharmacological strategies that have been shown to be more effective than pharmacological treatment and have fewer side effects than antipsychotic pharmacotherapy. On the example of the given clinical case, modern approaches to the correction of such complications and the management of this group of patients are shown. It seems appropriate to use memantine (akatinol memantine) in patients with neuropsychiatric symptoms of AD. In clinical studies, memantine has shown a positive effect in terms of reducing the rate of deterioration of general, cognitive, functional and behavioral parameters compared with treatment with antipsychotics. The drug is characterized by a minimum number of side effects and a limited range of contraindications. |
| first_indexed | 2024-04-10T02:00:27Z |
| format | Article |
| id | doaj.art-05e5143eae7041debd75219811e70d77 |
| institution | Directory Open Access Journal |
| issn | 2074-2711 2310-1342 |
| language | Russian |
| last_indexed | 2025-02-18T20:01:00Z |
| publishDate | 2022-06-01 |
| publisher | IMA-PRESS LLC |
| record_format | Article |
| series | Неврология, нейропсихиатрия, психосоматика |
| spelling | doaj.art-05e5143eae7041debd75219811e70d772024-10-17T16:15:30ZrusIMA-PRESS LLCНеврология, нейропсихиатрия, психосоматика2074-27112310-13422022-06-01143546110.14412/2074-2711-2022-3-54-611268Neuropsychiatric disorders correction in Alzheimer's diseaseN. N. Koberskaya0N.V. Sklifosovsky Institute of Clinical Medicine, I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)Behavioral and neuropsychiatric symptoms occur in 80% of patients with Alzheimer's disease (AD) and represent one of the most common reasons for early hospitalization and increased treatment costs. It is believed that the development of mental disorders (MD) is a marker of a number of additional adverse outcomes in patients with AD. The disease is accompanied by the development of other behavioral disorders, the most unpleasant of which are agitation (excitation) and aggression. The article discusses the causes and factors that can provoke the development of MD in AD. Traditionally used pharmacotherapeutic methods for the treatment of MD in AD in this age group have limited efficacy and are characterized by high toxicity. Antipsychotics are often associated with serious side effects and increased mortality in patients with dementia. A clinical case of AD with the development of neuropsychiatric disorders is presented. We discuss the issue of nonpharmacological strategies that have been shown to be more effective than pharmacological treatment and have fewer side effects than antipsychotic pharmacotherapy. On the example of the given clinical case, modern approaches to the correction of such complications and the management of this group of patients are shown. It seems appropriate to use memantine (akatinol memantine) in patients with neuropsychiatric symptoms of AD. In clinical studies, memantine has shown a positive effect in terms of reducing the rate of deterioration of general, cognitive, functional and behavioral parameters compared with treatment with antipsychotics. The drug is characterized by a minimum number of side effects and a limited range of contraindications.https://nnp.ima-press.net/nnp/article/view/1824alzheimer's diseasecognitive impairmentneuropsychiatric disordersmemantine |
| spellingShingle | N. N. Koberskaya Neuropsychiatric disorders correction in Alzheimer's disease Неврология, нейропсихиатрия, психосоматика alzheimer's disease cognitive impairment neuropsychiatric disorders memantine |
| title | Neuropsychiatric disorders correction in Alzheimer's disease |
| title_full | Neuropsychiatric disorders correction in Alzheimer's disease |
| title_fullStr | Neuropsychiatric disorders correction in Alzheimer's disease |
| title_full_unstemmed | Neuropsychiatric disorders correction in Alzheimer's disease |
| title_short | Neuropsychiatric disorders correction in Alzheimer's disease |
| title_sort | neuropsychiatric disorders correction in alzheimer s disease |
| topic | alzheimer's disease cognitive impairment neuropsychiatric disorders memantine |
| url | https://nnp.ima-press.net/nnp/article/view/1824 |
| work_keys_str_mv | AT nnkoberskaya neuropsychiatricdisorderscorrectioninalzheimersdisease |